Prescient Therapeutics Limited

ASX:PTX Stock Report

Market Cap: AU$32.2m

Prescient Therapeutics Management

Management criteria checks 3/4

Prescient Therapeutics' CEO is Steven Yatomi-Clarke, appointed in Feb 2016, has a tenure of 8.33 years. total yearly compensation is A$663.24K, comprised of 60.3% salary and 39.7% bonuses, including company stock and options. directly owns 1.39% of the company’s shares, worth A$447.80K. The average tenure of the management team and the board of directors is 8.3 years and 9.1 years respectively.

Key information

Steven Yatomi-Clarke

Chief executive officer

AU$663.2k

Total compensation

CEO salary percentage60.3%
CEO tenure8.3yrs
CEO ownership1.4%
Management average tenure8.3yrs
Board average tenure9.1yrs

Recent management updates

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Recent updates

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

CEO Compensation Analysis

How has Steven Yatomi-Clarke's remuneration changed compared to Prescient Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$8m

Sep 30 2023n/an/a

-AU$7m

Jun 30 2023AU$663kAU$400k

-AU$7m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$5m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022AU$771kAU$392k

-AU$5m

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$5m

Sep 30 2021n/an/a

-AU$5m

Jun 30 2021AU$800kAU$360k

-AU$4m

Mar 31 2021n/an/a

-AU$4m

Dec 31 2020n/an/a

-AU$3m

Sep 30 2020n/an/a

-AU$3m

Jun 30 2020AU$639kAU$392k

-AU$3m

Mar 31 2020n/an/a

-AU$4m

Dec 31 2019n/an/a

-AU$4m

Sep 30 2019n/an/a

-AU$4m

Jun 30 2019AU$586kAU$367k

-AU$4m

Mar 31 2019n/an/a

-AU$3m

Dec 31 2018n/an/a

-AU$3m

Sep 30 2018n/an/a

-AU$3m

Jun 30 2018AU$479kAU$330k

-AU$3m

Mar 31 2018n/an/a

-AU$3m

Dec 31 2017n/an/a

-AU$3m

Sep 30 2017n/an/a

-AU$3m

Jun 30 2017AU$502kAU$316k

-AU$3m

Compensation vs Market: Steven's total compensation ($USD442.54K) is above average for companies of similar size in the Australian market ($USD298.77K).

Compensation vs Earnings: Steven's compensation has been consistent with company performance over the past year.


CEO

Steven Yatomi-Clarke

8.3yrs

Tenure

AU$663,236

Compensation

Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...


Leadership Team

NamePositionTenureCompensationOwnership
Steven Yatomi-Clarke
MD, CEO & Director8.3yrsAU$663.24k1.39%
A$ 447.8k
Upaly Bahadure
Director of Clinical Affairs & Operationsless than a yearno datano data
Terrence Chew
Chief Medical Officer9.2yrsAU$157.36kno data
Rebecca Lim
Senior Vice President of Scientific Affairs2.4yrsno datano data
Melanie Leydin
Company Secretary9.3yrsAU$158.40kno data

8.3yrs

Average Tenure

Experienced Management: PTX's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Yatomi-Clarke
MD, CEO & Director9.6yrsAU$663.24k1.39%
A$ 447.8k
Steven Engle
Independent Non-Executive Chairman10yrsAU$106.05k0.027%
A$ 8.8k
James Campbell
Independent Non-Executive Director9.6yrsAU$65.26k0.049%
A$ 15.9k
Rodney Sinclair
Chairman of Clinical Advisory Board13yrsno datano data
Reinhard Dummer
Member of Clinical Advisory Board13yrsno datano data
Joshua Douglas
Member of Scientific Advisory Board9.8yrsno datano data
Farhad Ravandi
Member of Scientific Advisory Board8.6yrsno datano data
Jeffrey Lancet
Member of Scientific Advisory Board8.6yrsno datano data
H. Prince
Member of Scientific Advisory Board3.5yrsno datano data
Thomas Prebet
Member of Scientific Advisory Board8.4yrsno datano data
Allen Ebens
Non-Executive Director4yrsAU$65.26kno data
Phillip Darcy
Member of Scientific Advisory Board3.8yrsno datano data

9.1yrs

Average Tenure

Experienced Board: PTX's board of directors are considered experienced (9.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.